Published on 8 Mar 2024 on Simply Wall St. via Yahoo Finance

When Will BioLife Solutions, Inc. (NASDAQ:BLFS) Become Profitable?

BioLife Solutions, Inc. (NASDAQ:BLFS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The US$782m market-cap company announced a latest loss of US$66m on 31 December 2023 for its most recent financial year result. As path to profitability is the topic on BioLife Solutions' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

See our latest analysis for BioLife Solutions

BioLife Solutions is bordering on breakeven, according to the 8 American Life Sciences analysts. They expect the company to post a final loss in 2025, before turning a profit of US$7.4m in 2026. The company is therefore projected to breakeven around 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 61% is expected, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.